SEC Form 4 · accession 0001127602-18-011560
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & CEO · Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 12, 2018 | M | 21,512 | $52.65 | A | 21,652 | D | |
| Common StockF2 | Mar 12, 2018 | S | 5,313 | $115.1832 | D | 16,339 | D | |
| Common StockF3 | Mar 12, 2018 | S | 16,179 | $115.9947 | D | 160 | D | |
| Common Stock | Mar 12, 2018 | S | 20 | $116.58 | D | 140 | D | |
| Common Stock | Mar 13, 2018 | M | 21,512 | $52.65 | A | 21,652 | D | |
| Common StockF4 | Mar 13, 2018 | S | 10,220 | $113.5856 | D | 11,432 | D | |
| Common StockF5 | Mar 13, 2018 | S | 6,590 | $114.6193 | D | 4,842 | D | |
| Common StockF6 | Mar 13, 2018 | S | 4,502 | $115.5397 | D | 340 | D | |
| Common Stock | Mar 13, 2018 | S | 200 | $116.51 | D | 140 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $52.65 | Mar 12, 2018 | M | 21,512 | D | Dec 31, 2009 | Dec 31, 2019 | Common Stock | 21,512 | 408,732 | D |
| Stock Options | $52.65 | Mar 13, 2018 | M | 21,512 | D | Dec 31, 2009 | Dec 31, 2019 | Common Stock | 21,512 | 387,220 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan (the "plan") entered into by the reporting person. The plan is designed to exercise and sell up to 430,244 stock options over a four-week period ending on April 9, 2018, in equal tranches of approximately 21,500 shares per day.
- F2This transaction was executed in multiple trades at prices ranging from $114.57 to $115.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $115.57 to $116.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $113.085 to $114.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $114.095 to $115.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $115.19 to $116.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.